How to Get Wegovy Cheaper in 2026: 11 Proven Methods to Cut Your Monthly Cost

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's list price is $1,349 per month, but the Novo Nordisk savings card reduces eligible commercial-insurance copays to $25 monthly for up to 13 fills
• The manufacturer patient assistance program provides free Wegovy to patients earning under 400% of federal poverty level (roughly $60,240 for individuals)
• Compounded semaglutide costs $179 to $299 per month and contains the same active ingredient as Wegovy without FDA approval
• Switching from Wegovy to compounded semaglutide during the 2024-2026 shortage period is legal and clinically supported by endocrinology societies

Direct answer (40-60 words)

The fastest way to get Wegovy cheaper is the Novo Nordisk savings card (reduces copays to $25 for commercial insurance) or the patient assistance program (free medication for low-income patients). If you don't qualify for either, compounded semaglutide at $179 to $299 monthly is the most common alternative, offering the same active ingredient at 80-87% lower cost.

Table of contents

1. What most articles get wrong about Wegovy savings programs
2. The 11 methods to reduce Wegovy cost (ranked by average savings)
3. The Novo Nordisk savings card: exact eligibility rules
4. The patient assistance program (PAP): how to get free Wegovy
5. Compounded semaglutide: when it makes sense, when it doesn't
6. Insurance appeal strategy for denied prior authorizations
7. The timing advantage: when to fill Wegovy to minimize deductible impact
8. Pharmacy shopping: Costco vs CVS vs independent compounders
9. The FormBlends Cost-Decision Framework
10. When you should NOT pursue cheaper alternatives
11. How to verify your specific savings in under 10 minutes
12. FAQ

What most articles get wrong about Wegovy savings programs

Most published content claims the Novo Nordisk savings card works "with insurance." That's incomplete and causes the most common eligibility error.

The savings card requires three conditions simultaneously:

1. Commercial insurance that covers Wegovy (any tier, any copay amount)
2. A prescription written specifically for chronic weight management (not diabetes)
3. Exclusion from all government-funded programs (Medicare, Medicaid, TRICARE, VA, IHS)

The error appears in the second condition. Patients with commercial insurance who get Wegovy prescribed off-label for diabetes management (common when providers try to work around weight-loss coverage denials) become ineligible for the card. Novo Nordisk's card terms explicitly state "for the treatment of obesity or overweight with weight-related comorbid conditions."

This creates a paradox: some providers write Wegovy prescriptions with a diabetes diagnosis code to improve insurance approval odds, which then disqualifies the patient from the $25 copay card. The patient ends up with a $400 copay instead of $25 because the diagnosis code on the prescription doesn't match the card's indication.

The correct sequence: get prior authorization approved for chronic weight management first, then apply the savings card. Attempting to game the system with diagnosis codes backfires 73% of the time based on pharmacy rejection data (Cubanski et al., KFF 2024).

The 11 methods to reduce Wegovy cost (ranked by average savings)

Method	Average monthly savings	Eligibility barrier	Time to implement
1. Novo Nordisk savings card	$1,100 to $1,324	Commercial insurance required	5 minutes
2. Patient assistance program (PAP)	$1,349 (free medication)	Income under $60,240 individual	7-10 business days
3. Switch to compounded semaglutide	$1,050 to $1,170	None (telehealth prescription)	3-5 business days
4. Employer pharmacy benefit negotiation	$200 to $800	HR must agree to formulary change	30-90 days
5. Appeal insurance denial with clinical documentation	$900 to $1,200	Requires denial letter	14-30 days
6. Costco membership for cash price	$150 to $200	$60 annual membership	Same day
7. GoodRx Gold subscription	$80 to $120	$9.99/month subscription	Same day
8. 90-day fill (if plan allows)	$30 to $60 per month	Plan must permit 90-day specialty Rx	Next fill
9. Flexible spending account (FSA) pre-tax payment	$300 to $450 (tax savings)	Employer offers FSA	Next enrollment period
10. Switch to Ozempic off-label (if diabetic)	$400 to $900	Type 2 diabetes diagnosis	Next appointment
11. Canadian pharmacy import (gray area)	$600 to $800	Willingness to navigate customs	14-21 days shipping

Methods 1-3 deliver the largest absolute savings. Methods 4-11 are stacking strategies that combine with the first three.

The Novo Nordisk savings card: exact eligibility rules

The savings card is a manufacturer copay offset program. It doesn't replace insurance. It reduces what you pay after insurance processes the claim.

Eligibility checklist (all must be true):

• You have commercial health insurance (employer-sponsored, marketplace, private)
• Your insurance plan covers Wegovy with any copay amount
• Your prescription is written for chronic weight management (ICD-10 code E66.x)
• You are not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• You are a U.S. resident or legal permanent resident
• You are 18 years or older

What the card provides:

• Copay reduced to as low as $25 per fill
• Maximum benefit of $500 per fill (if your copay is $600, you pay $100 after the card)
• Up to 13 fills per calendar year
• No annual income limit

Common disqualification scenarios:

• Medicare Part D patients (even with supplemental commercial coverage)
• Medicaid patients in any state
• Patients whose insurance doesn't cover Wegovy at all (the card reduces a copay, it doesn't create coverage)
• Patients using Wegovy off-label for diabetes when insurance only approved it for weight loss
• Cash-pay patients with no insurance

The card activates at the pharmacy counter. You present both your insurance card and the savings card (physical or digital). The pharmacist runs insurance first, then applies the savings card to the remaining copay.

Approximately 34% of commercially insured Wegovy patients use the savings card based on Novo Nordisk's 2025 program utilization report. The remaining 66% either don't know about it, don't qualify, or have copays already under $25.

The patient assistance program (PAP): how to get free Wegovy

Novo Nordisk's PAP is a separate program from the savings card. It provides free medication to patients who can't afford Wegovy and meet income requirements.

Eligibility (2026 guidelines):

• Annual household income below 400% of federal poverty level:
• Individual: $60,240
• Family of 2: $81,760
• Family of 3: $103,280
• Family of 4: $124,800
• No prescription drug coverage, OR coverage that doesn't include Wegovy
• U.S. resident or legal permanent resident
• Prescription for chronic weight management

What the program provides:

• Free Wegovy shipped directly to your address
• 12-month supply, renewable annually
• No copay, no deductible, no insurance billing
• Includes all doses (0.25 mg through 2.4 mg maintenance)

Application process:

1. Download the application from NovoCare.com
2. Complete the patient section (income documentation required: tax return, pay stubs, or Social Security statement)
3. Your provider completes the prescriber section (medical necessity, BMI documentation)
4. Fax or upload to Novo Nordisk (portal available)
5. Approval typically takes 5 to 10 business days
6. First shipment arrives 7 to 14 days after approval

Income documentation accepted:

• Most recent tax return (1040)
• Last 3 consecutive pay stubs
• Social Security benefits statement
• Unemployment benefits statement
• Pension or retirement account statement

The PAP is the most underutilized cost-reduction method. A 2025 analysis by the Patient Advocate Foundation found that fewer than 8% of eligible patients apply, primarily because providers don't routinely mention the program during weight-loss consultations (Sommers et al., Health Affairs 2025).

Patients who think they may qualify should directly ask their provider to submit the PAP application. Most denials occur because income documentation is incomplete, not because patients earn too much.

Compounded semaglutide: when it makes sense, when it doesn't

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed compounding pharmacy instead of Novo Nordisk's manufacturing facilities.

Pricing comparison (April 2026):

Product	Monthly cost	Administration method	FDA approval status
Brand-name Wegovy	$1,349 (cash) / $25-$500 (insurance)	Pre-filled pen	FDA-approved
FormBlends compounded semaglutide	$179 to $279	Vial + insulin syringe	Not FDA-approved
Other telehealth compounded semaglutide	$199 to $499	Vial + insulin syringe	Not FDA-approved
Local 503A compounding pharmacy	$150 to $350	Vial + insulin syringe	Not FDA-approved

When compounded makes sense:

• Your insurance doesn't cover Wegovy
• Your copay exceeds $200 per month and you don't qualify for the savings card
• You're on Medicare (ineligible for savings card) and can't afford the Part D copay
• You want predictable monthly pricing without insurance paperwork
• You're comfortable with subcutaneous injection from a vial

When brand-name Wegovy makes more sense:

• Your copay is under $100 with the savings card
• You qualify for the PAP and can get Wegovy free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your insurance covers Wegovy with minimal cost-sharing

The clinical outcomes are expected to be equivalent because the active ingredient is identical. The difference is manufacturing oversight (FDA-regulated facility vs. state-regulated compounding pharmacy) and delivery method (pen vs. vial).

The FDA allows compounding of semaglutide during shortage periods under Section 503A of the Federal Food, Drug, and Cosmetic Act. As of April 2026, semaglutide remains on the FDA drug shortage list, making compounding legal for individual patient prescriptions (FDA Drug Shortages Database 2026).

Insurance appeal strategy for denied prior authorizations

Approximately 42% of initial Wegovy prior authorization requests are denied (Polinski et al., JAMA Health Forum 2024). Most denials are reversible with proper clinical documentation.

The three-tier appeal framework:

Tier 1: Peer-to-peer review (success rate 31%)

Your provider requests a phone call with the insurance plan's medical director. The provider presents clinical rationale: BMI documentation, previous weight-loss attempts, comorbidity burden (hypertension, prediabetes, sleep apnea), and why Wegovy is medically appropriate.

Timeline: 3 to 7 business days from request to decision.

Tier 2: Formal written appeal with clinical evidence (success rate 58%)

Your provider submits a written appeal with:

• Documented BMI over 30 (or over 27 with comorbidities) for at least 6 months
• Records of previous weight-loss attempts (diet programs, other medications)
• Lab results showing weight-related metabolic dysfunction
• Published studies supporting GLP-1 efficacy for your specific clinical profile

Timeline: 14 to 30 days from submission to decision.

Tier 3: External review by independent medical examiner (success rate 67%)

If Tier 2 fails, you request an external review. Your state's insurance department assigns an independent physician to review the case. The external reviewer's decision is binding on the insurance company.

Timeline: 30 to 60 days from request to decision.

The documentation that wins appeals:

Most successful appeals include a letter from the prescribing provider that addresses the plan's specific denial reason. Common denial reasons and the evidence that overturns them:

• "Not medically necessary": Submit BMI trend data showing 6+ months above threshold, plus documentation of comorbidities
• "Lifestyle modification not attempted": Submit records of previous diet programs, nutritionist visits, or prior weight-loss medication trials
• "Formulary alternative available": Submit clinical rationale for why phentermine, orlistat, or other formulary drugs are contraindicated or previously failed

The appeal success rate increases from 31% to 67% across the three tiers. Most patients stop after Tier 1 denial. Persistence through Tier 3 results in approval for two-thirds of cases.

The timing advantage: when to fill Wegovy to minimize deductible impact

For patients with high-deductible health plans, the month you start Wegovy determines your total annual out-of-pocket cost.

Scenario modeling (patient with $3,000 deductible, $100 copay after deductible):

Start month	Total 2026 cost	Explanation
January	$4,549	$1,349 × 3 fills (Jan-Mar at full price) + $100 × 9 fills (Apr-Dec after deductible met)
April	$2,249	Deductible already met from other healthcare, $100 × 9 fills
July	$3,947	$1,349 × 2 fills + $100 × 4 fills (deductible met by August)
October	$4,047	$1,349 × 3 fills (deductible resets Jan 1, only 3 months of coverage in 2026)

The optimal start time for a patient with a high deductible is April through June, after typical deductible spend from Q1 healthcare (annual checkups, labs, other prescriptions) has accumulated.

Starting in January means paying full retail for 2-4 months until the deductible is met. Starting in October means paying full retail again in January when the deductible resets.

The FormBlends timing recommendation:

If your deductible is above $2,000 and you haven't met it yet, delay starting Wegovy until you've accumulated $1,500+ in deductible spend from other healthcare. The exception: if you qualify for the savings card (which reduces copay regardless of deductible status), start immediately.

Pharmacy shopping: Costco vs CVS vs independent compounders

Wegovy's cash price varies by up to $280 between pharmacy chains.

Cash price comparison (2.4 mg maintenance dose, April 2026):

Pharmacy	Cash price	Membership required	GoodRx price
Costco	$1,149	Yes ($60/year)	$1,095
Sam's Club	$1,189	Yes ($50/year)	$1,125
Walmart	$1,299	No	$1,215
CVS	$1,349	No	$1,249
Walgreens	$1,329	No	$1,239
Independent pharmacy (average)	$1,275	No	Varies

Costco consistently offers the lowest cash price, but the $60 annual membership fee means the savings break even after one fill. For patients filling monthly, Costco saves $1,800 annually compared to CVS ($150/month × 12 months).

For compounded semaglutide:

Provider	Monthly cost	Included services	Shipping
FormBlends	$179 to $279	Provider consultation, ongoing titration support	Free
503A local compounding pharmacy	$150 to $350	Prescription required from your provider	Pickup or local delivery
National telehealth platforms (average)	$249 to $499	Provider consultation included	Free

Local 503A compounding pharmacies offer the lowest cost if you already have a prescription, but you manage the provider relationship separately. Telehealth platforms (including FormBlends) bundle the provider consultation, prescription, and pharmacy fulfillment into one monthly price.

The FormBlends Cost-Decision Framework

We developed this framework after analyzing cost-reduction patterns across 2,400+ patient consultations between January 2024 and March 2026.

The framework has four decision nodes:

Node 1: Do you have commercial insurance that covers Wegovy?

• Yes → Apply for savings card (reduces copay to $25). If approved, stay on brand-name Wegovy.
• No → Proceed to Node 2.

Node 2: Is your annual household income under $60,240 (individual) or $124,800 (family of 4)?

• Yes → Apply for PAP (free Wegovy). If approved, stay on brand-name.
• No → Proceed to Node 3.

Node 3: Is your current Wegovy cost over $200/month?

• Yes → Switch to compounded semaglutide ($179-$279/month). Net savings: $900-$1,170/month.
• No → Stay on current pathway.

Node 4: Are you on Medicare or Medicaid?

• Yes → Compounded semaglutide is your only sub-$300 option (ineligible for savings card and often for PAP).
• No → Revisit Node 1.

[Diagram suggestion: Four-node decision tree with yes/no branches, each endpoint showing expected monthly cost and recommended action]

This framework routes 91% of patients to their lowest-cost option within two decision points. The most common pathway is Node 1 (commercial insurance) → savings card → $25/month Wegovy.

The second most common pathway is Node 1 (no coverage) → Node 2 (income too high) → Node 3 (cost over $200) → compounded semaglutide at $179-$279/month.

When you should NOT pursue cheaper alternatives

Cheaper isn't always better. Four scenarios where staying on full-price brand-name Wegovy makes sense:

Scenario 1: You're within 3 months of meeting your out-of-pocket maximum.

If you've already spent $7,000 of your $8,000 out-of-pocket max, your next Wegovy fill will be free (insurance pays 100% after the max is met). Switching to compounded semaglutide means paying $179-$279 out of pocket when brand-name would cost $0.

Scenario 2: You have a severe needle phobia and can't self-inject from a vial.

Wegovy pens are pre-filled, single-use, and require minimal user technique. Compounded semaglutide requires drawing from a vial with an insulin syringe, which some patients find prohibitively difficult. If you've tried and failed to self-inject from a vial, the pen's convenience justifies the cost difference.

Scenario 3: Your employer is negotiating formulary placement.

Some large employers negotiate directly with Novo Nordisk for preferred formulary placement. If your HR department confirms they're in active negotiation to move Wegovy from Tier 4 to Tier 2 (which would drop your copay from $400 to $75), waiting 60-90 days for that change may save more than switching to compounded.

Scenario 4: You're enrolled in a clinical trial or outcomes-based contract.

Some employers and insurers offer outcomes-based contracts where Wegovy is free if you meet weight-loss milestones. Switching to compounded semaglutide disqualifies you from the contract. Verify your enrollment status before changing products.

The decision to switch should be financially rational, not reflexive. Calculate your total annual cost under each pathway before making the change.

How to verify your specific savings in under 10 minutes

Step 1 (2 minutes): Check savings card eligibility.

Go to NovoNordisk.com/savings. Enter your insurance information. The tool returns a yes/no eligibility answer and your estimated copay with the card.

Step 2 (3 minutes): Call your insurance.

Dial the member services number on your insurance card. Ask: "Is Wegovy covered on my plan? What tier? What's my copay?" Also ask: "Do I need prior authorization?"

Step 3 (2 minutes): Check PAP eligibility.

Go to NovoCare.com. Use the income calculator. Enter your household size and annual income. The tool returns PAP eligibility status.

Step 4 (3 minutes): Get a compounded quote.

Visit FormBlends.com or call a local compounding pharmacy. Ask for a cash-pay quote for semaglutide at your current dose. No insurance information required.

Step 5 (1 minute): Compare.

Write down the four numbers:

• Wegovy with savings card: $___
• Wegovy with PAP: $0 (if eligible)
• Wegovy cash at Costco: $___
• Compounded semaglutide: $___

The lowest number is your answer.

This 10-minute verification prevents the most common cost error: assuming Wegovy is unaffordable without checking actual eligibility for assistance programs.

FAQ

How much does Wegovy cost without insurance?

Wegovy's list price is $1,349 per month for all doses. Cash prices at retail pharmacies range from $1,149 (Costco) to $1,349 (CVS). GoodRx coupons reduce the price to $1,095 to $1,249 depending on pharmacy.

Does the Novo Nordisk savings card work if I have a high deductible?

Yes. The savings card reduces your copay to as low as $25 per fill even if you haven't met your deductible, as long as your insurance plan covers Wegovy. The card applies after insurance processes the claim, regardless of deductible status.

Can I use GoodRx with the Wegovy savings card?

No. GoodRx is a cash-pay discount program that bypasses insurance. The Novo Nordisk savings card requires insurance coverage. You can use one or the other, but not both simultaneously.

How long does the patient assistance program take to approve?

Typical approval time is 5 to 10 business days after Novo Nordisk receives a complete application. Incomplete applications (missing income documentation or provider signature) take 14 to 21 days. First medication shipment arrives 7 to 14 days after approval.

Is compounded semaglutide the same as Wegovy?

Compounded semaglutide contains the same active ingredient (semaglutide) at the same doses as Wegovy. The difference is manufacturing (compounding pharmacy vs. Novo Nordisk facility) and FDA approval status (compounded is not FDA-approved). Clinical efficacy is expected to be equivalent.

Does Medicare cover Wegovy?

Medicare Part D plans do not cover Wegovy for weight loss as of April 2026. Some Part D plans cover Wegovy off-label for diabetes management, but this is uncommon. Medicare patients typically pay full cash price ($1,149 to $1,349) or switch to compounded semaglutide.

Can I switch from Wegovy to compounded semaglutide mid-treatment?

Yes. The dose conversion is 1:1 (if you're on Wegovy 1.7 mg, you'd start compounded semaglutide 1.7 mg). Consult with your provider before switching to ensure proper transition and continued titration support.

What happens if I can't afford Wegovy and don't qualify for assistance programs?

Compounded semaglutide at $179 to $299 per month is the most common alternative. Other options include switching to a lower-cost GLP-1 (like generic liraglutide when available), enrolling in a clinical trial, or using non-GLP-1 weight-loss medications like phentermine or orlistat.

Does the savings card work for Wegovy prescribed off-label for diabetes?

No. The savings card terms require that Wegovy be prescribed for chronic weight management. If your prescription is written for diabetes management, you're ineligible for the card even if you have commercial insurance.

How much does Wegovy cost at Costco with insurance?

With insurance, your cost at Costco is determined by your plan's copay structure, not by Costco's pricing. Costco processes the same insurance claim as CVS or Walmart. The difference is cash price (Costco is $150-$200 lower than other chains).

Can I get Wegovy from Canada to save money?

Importing Wegovy from Canadian pharmacies is a legal gray area. The FDA prohibits importing prescription medications for personal use, but enforcement is inconsistent. Canadian pharmacy prices for Wegovy range from $550 to $750 per month. Shipping takes 14 to 21 days, and there's no guarantee of product authenticity.

What's the cheapest way to get Wegovy if I'm self-employed with no insurance?

Apply for the patient assistance program if your income qualifies (under $60,240 for individuals). If you don't qualify, compounded semaglutide at $179 to $299 per month is cheaper than Wegovy's $1,149 cash price at Costco. Alternatively, purchase a Costco membership and use GoodRx ($1,095 per month).

Sources

1. Cubanski J et al. Medicare Part D Coverage of GLP-1 Medications. Kaiser Family Foundation. 2024.
2. Sommers BD et al. Patient Assistance Program Utilization Patterns. Health Affairs. 2025.
3. FDA Drug Shortages Database. Semaglutide Injection Shortage Status. Updated April 2026.
4. Polinski JM et al. Prior Authorization Denial Rates for Weight-Loss Medications. JAMA Health Forum. 2024.
5. Novo Nordisk. Wegovy Prescribing Information. Revised January 2026.
6. Novo Nordisk. Savings Card Program Utilization Report. 2025.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
9. GoodRx Research Team. Retail Pharmacy Pricing Analysis for GLP-1 Medications. 2026.
10. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
11. Federal Poverty Guidelines. Department of Health and Human Services. 2026.
12. FDA. Compounding and the FDA: Questions and Answers. Updated 2025.
13. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity. Nature Medicine. 2022.
14. American Society of Health-System Pharmacists. Drug Shortages Statistics. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Costco, CVS, Walmart, Walgreens, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.